top_image
We have a robust pipeline of internally-developed novel biologics and biosimilars targeting the most debilitating diseases – autoimmune diseases, targeted & immuno-oncology and infectious diseases. We are leveraging our Trimer-Tag© technology platform to develop novel trimerized drug candidates.